ANDOVER, Mass. and HAIFA, Israel, March 11, 2026 /PRNewswire/ — MeMed, a leader in advanced host-response diagnostics, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation (BDD) to MeMed BV Flex™, a test designed to accurately distinguish between bacterial and viral infections based on the body’s immune response.

Read more here.